Core Viewpoint - Semaglutide, marketed as a weight loss drug, has gained popularity among users who report significant weight loss and improved body composition after using it for a short period [2]. Group 1: Product Approval and Mechanism - Semaglutide tablets have been approved for use in China for the treatment of type 2 diabetes in adults by the National Medical Products Administration (NMPA) in 2024 [3]. - The drug works by activating GLP-1 receptors, which helps lower blood sugar and body weight through multiple mechanisms, including promoting insulin secretion, inhibiting glucagon secretion, delaying gastric emptying, and suppressing appetite [4]. - Semaglutide oral tablets are the first GLP-1 receptor agonist available in oral form, significantly enhancing bioavailability by approximately 100 times due to the absorption enhancer SNAC [4]. Group 2: Clinical Research Findings - The global PIONEER clinical trial, involving 11,505 patients, demonstrated that semaglutide not only significantly lowers blood sugar but also provides benefits in weight loss, blood pressure reduction, and lipid regulation [6]. - In the PIONEER 6 study, semaglutide oral tablets showed excellent cardiovascular safety, particularly in patients with cardiovascular diseases or risk factors [6]. - The PIONEER PLUS trial results indicated that higher doses of semaglutide (25mg and 50mg) resulted in greater reductions in HbA1c levels and weight loss compared to the 14mg group, with weight loss averaging 7.0kg and 9.2kg respectively [7]. Group 3: Weight Loss Efficacy - The OASIS 4 study revealed that participants using semaglutide experienced an average weight loss of 13.6%, compared to only 2.2% in the placebo group, with potential weight loss reaching 16.6% if all participants completed the treatment [9].